Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:BCDANASDAQ:CYTROTCMKTS:ENZNNASDAQ:PALI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$0.36-3.8%$0.41$0.32▼$2.92$9.81M1.47320,714 shs21,024 shsCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsENZNEnzon Pharmaceuticals$0.08$0.08$0.06▼$0.23N/A0.336,053 shs19 shsPALIPalisade Bio$5.97-6.0%$5.74$3.82▼$36.60$5.07M1.33840,078 shs26,291 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.63%-96.12%-92.66%BCDABioCardia+0.93%+3.10%-6.30%-10.30%-81.03%CYTRLadRx0.00%0.00%0.00%0.00%0.00%ENZNEnzon Pharmaceuticals-0.04%+7.69%+8.29%-8.27%-61.97%PALIPalisade Bio+7.26%-3.79%+16.69%-17.16%-72.51%See this before next week's Fed meeting (Ad)See this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia2.8231 of 5 stars3.35.00.00.02.23.30.0CYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APALIPalisade Bio3.1063 of 5 stars3.55.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ABCDABioCardia2.50Moderate Buy$4.00996.19% UpsideCYTRLadRxN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/APALIPalisade Bio3.00Buy$131.252,098.49% UpsideCurrent Analyst RatingsLatest ENZN, PALI, ACOR, CYTR, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024PALIPalisade BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.50(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00BCDABioCardia$480K20.43N/AN/A($0.07) per share-5.21CYTRLadRxN/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/APALIPalisade Bio$250K20.30N/AN/A$18.29 per share0.33Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)BCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)CYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AENZNEnzon Pharmaceuticals$1.37M$0.017.80∞N/AN/A46.47%2.92%N/APALIPalisade Bio-$12.30M-$27.14N/A∞N/AN/A-89.68%-76.18%5/10/2024 (Estimated)Latest ENZN, PALI, ACOR, CYTR, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023BCDABioCardia-$0.11-$0.09+$0.02-$0.09$0.20 million$0.01 million3/26/2024Q4 2023PALIPalisade BioN/A-$3.75-$3.75-$3.75N/AN/A3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCDABioCardiaN/A0.400.40CYTRLadRxN/AN/AN/AENZNEnzon PharmaceuticalsN/A27.6227.62PALIPalisade BioN/A5.155.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCDABioCardia20.57%CYTRLadRxN/AENZNEnzon PharmaceuticalsN/APALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCDABioCardia23.90%CYTRLadRxN/AENZNEnzon Pharmaceuticals0.27%PALIPalisade Bio2.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCDABioCardia1626.87 million20.45 millionOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionablePALIPalisade Bio9850,000833,000Not OptionableENZN, PALI, ACOR, CYTR, and BCDA HeadlinesSourceHeadlinePalisade Bio, Strand Life Sciences team up on colitis drug researchmsn.com - April 23 at 2:35 PMPalisade Bio stock rallies on Strand Life Sciences partnershipinvezz.com - April 23 at 2:35 PMWhy Palisade Bio Stock Is Up Todaymsn.com - April 23 at 2:35 PMPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approachfinance.yahoo.com - April 23 at 9:34 AMPalisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approachglobenewswire.com - April 23 at 8:30 AMLooking Into Palisade Bio's Recent Short Interestbenzinga.com - April 19 at 2:14 PMPalisade Bio shows successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor formbioworld.com - April 18 at 7:44 PMPalisade Bio completes its analysis evaluating ex-vivo bioactivation of PALI-2108 for patients affected by ulcerative colitispharmabiz.com - April 18 at 9:44 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)markets.businessinsider.com - April 17 at 5:31 PMPalisade Bio (NASDAQ:PALI) Given Buy Rating at Maxim Groupamericanbankingnews.com - April 17 at 3:56 AMHow Apple Car Key Works (and Why It Still Hasn’t Caught On)msn.com - April 17 at 2:29 AMBiopharma Stocks in Play - Palisade Bio, Inc. (Nasdaq: PALI) Soars on News it Demonstrated Bioactivation of PALI-2108 In Ex-Vivo Studyinvestorideas.com - April 16 at 9:28 PMPalisade Bio stock rallies nearly 100% on colitis drug analysismsn.com - April 16 at 9:28 PMPalisade Bio Shares Surge 80% After Lab Study Results for Ulcerative Colitis Treatmentmarketwatch.com - April 16 at 4:28 PMWhy Palisade Bio Stock Is Soaring Todaymsn.com - April 16 at 4:28 PMWhy Is Palisade Bio (PALI) Stock Up 57% Today?investorplace.com - April 16 at 11:22 AMPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stoolfinance.yahoo.com - April 16 at 8:43 AMPalisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stoolglobenewswire.com - April 16 at 8:30 AMPalisade Bio advances ulcerative colitis treatment to Phase 1 studyuk.investing.com - April 12 at 12:54 PMPalisade Bio to Participate in the Virtual Investor Lunch Break Eventglobenewswire.com - April 11 at 9:15 AMPalisade Bio stock slides 8% amid colitis drug presentationmsn.com - April 10 at 1:23 PMPalisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™finance.yahoo.com - April 10 at 8:23 AMPalisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™globenewswire.com - April 10 at 8:15 AMPalisade Bio Inc 7NSmorningstar.com - April 6 at 12:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.LadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Palisade BioNASDAQ:PALIPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.